Raghu et al. designed a similar multicenter study with 117 patients and reported a slower decline in lung function over 28 weeks, as infusions of human PTX-2 were administered to patients with IPF (12). The gene discussed is APCS; the disease is idiopathic pulmonary fibrosis.